HEPA Hepion Pharmaceuticals, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1583771 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY20.4%
TTM EPS YoY98.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-166.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets180.2%
Debt / equity—
Current ratio4.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio-120.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $0 | $0 | $0 |
| R&D expense | $445,512 | $11.85M | $35.64M | $33.27M | $20.40M |
| SG&A expense | $3.32M | $7.50M | $9.62M | $10.35M | $10.01M |
| Operating income | -$4.16M | -$19.35M | -$48.45M | -$45.49M | -$30.40M |
| Interest expense | — | — | $9,465 | $10,164 | $8,859 |
| Pretax income | -$8.28M | -$16.16M | -$49.34M | -$45.08M | -$32.72M |
| Income tax | — | -$2.97M | -$409,022 | -$2.88M | $0 |
| Net income | -$8.28M | -$13.19M | -$48.93M | -$42.20M | -$32.72M |
| EBITDA | — | -$19.32M | -$48.38M | -$45.41M | -$30.32M |
| EPS (basic) | -0.88 | -107.35 | -616.07 | -11.90 | -0.47 |
| EPS (diluted) | -0.88 | -107.35 | -616.07 | -11.90 | -0.47 |
| Weighted avg. shares (diluted) | 9.41M | 122,894 | 79,416 | 3.81M | 70.29M |
| Balance sheet | |||||
| Cash & equivalents | $1.83M | $406,408 | $14.79M | $51.19M | $91.35M |
| Current assets | $3.07M | $1.61M | $17.49M | $56.50M | $97.45M |
| PP&E, net | — | — | $29,487 | $81,620 | $152,772 |
| Goodwill | — | — | — | $0 | $1.87M |
| Total assets | $3.07M | $1.61M | $18.09M | $60.24M | $103.55M |
| Current liabilities | $299,383 | $3.14M | $5.29M | $7.89M | $8.21M |
| Total liabilities | $402,405 | $3.48M | $10.81M | $10.39M | $10.56M |
| Shareholders' equity | $2.67M | -$1.86M | $7.28M | $49.86M | $93.00M |
| Shares outstanding | 11.62M | 139,168 | 96,375 | 3.81M | 76.23M |
| Cash flow statement | |||||
| Operating cash flow | -$3.27M | -$18.22M | -$40.89M | -$34.96M | -$31.22M |
| Capital expenditure | — | — | $14,304 | $16,336 | $130,405 |
| Free cash flow | — | — | -$40.90M | -$34.98M | -$31.35M |
| Investing cash flow | -$132,117 | -$600,000 | -$14,304 | -$14,070 | -$130,405 |
| Financing cash flow | $4.83M | $4.35M | $4.49M | -$5.14M | $81.98M |
| Depreciation & amortization | — | $30,758 | $67,131 | $77,461 | $86,073 |
| Stock-based compensation | $20,783 | $791,645 | $1.34M | $2.55M | $4.67M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.